Special Issue "Emerging Pain Targets and Therapy"

Quicklinks

A special issue of Pharmaceuticals (ISSN 1424-8247).

Deadline for manuscript submissions: closed (31 July 2012)

Special Issue Editor

Guest Editor
Dr. Kim Lawson
Department of Biosciences, Biomedical Research Centre, Sheffield Hallam University, Faculty of Health and Wellbeing, City Campus, Sheffield, S1 1WB, UK
E-Mail: k.lawson@shu.ac.uk
Interests: fibromyalgia; pain; potassium channels; drug design/discovery

Special Issue Information

Dear Colleagues,

Pain remains a major clinical challenge with the management of pain the most frequent issue encountered by clinicians. Many current analgesics are limited by serious unwanted effects, while for some pain conditions there are no effective analgesics. Advances in molecular biological techniques that have enabled the discovery of specific molecules involved in pain production have contributed to a better understanding of pain and the mechanisms of different types of pain and are providing clues for the development of novel pharmacotherapies for specific pain types. This increased understanding of pain physiology has offered a number of potential targets (e.g. TRPV1, voltage-gated sodium channels, calcium channels, glutamate receptors, cannabinoids) for future treatments, in particular for neuropathic and chronic pain. This special issue is intended to provide the reader with an insight into the progress made in this field through novel contributions of original papers and critical reviews.

Dr. Kim Lawson
Guest Editor

Keywords

  • pain
  • pain pathways
  • emerging targets
  • molecular biology
  • novel therapies
  • ion channels

Published Papers (6 papers)

Pharmaceuticals 2012, 5(10), 1045-1053; doi:10.3390/ph5101045
Received: 2 July 2012; in revised form: 6 September 2012 / Accepted: 17 September 2012 / Published: 27 September 2012
Show/Hide Abstract | Download PDF Full-text (209 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2012, 5(8), 837-852; doi:10.3390/ph5080837
Received: 29 June 2012; in revised form: 2 August 2012 / Accepted: 15 August 2012 / Published: 17 August 2012
Show/Hide Abstract | Download PDF Full-text (140 KB) | View HTML Full-text | Download XML Full-text

Pharmaceuticals 2012, 5(3), 249-278; doi:10.3390/ph5030249
Received: 4 January 2012; in revised form: 4 February 2012 / Accepted: 15 February 2012 / Published: 23 February 2012
Show/Hide Abstract | Download PDF Full-text (287 KB) | Download XML Full-text

Pharmaceuticals 2012, 5(2), 114-132; doi:10.3390/ph5020114
Received: 18 November 2011; in revised form: 18 January 2012 / Accepted: 26 January 2012 / Published: 2 February 2012
Show/Hide Abstract | Download PDF Full-text (473 KB) | Download XML Full-text

Pharmaceuticals 2012, 5(1), 16-48; doi:10.3390/ph5010016
Received: 16 November 2011; in revised form: 16 December 2011 / Accepted: 21 December 2011 / Published: 27 December 2011
Show/Hide Abstract | Download PDF Full-text (1565 KB) | Download XML Full-text
abstract graphic

Pharmaceuticals 2011, 4(11), 1503-1517; doi:10.3390/ph4111503
Received: 12 October 2011; in revised form: 26 October 2011 / Accepted: 7 November 2011 / Published: 11 November 2011
Show/Hide Abstract | Download PDF Full-text (1086 KB) | View HTML Full-text | Download XML Full-text |  Supplementary Files

Last update: 4 March 2014

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert